Allergologia et immunopathologia最新文献

{"title":"Rapid drug desensitization with chemotherapy: when should omalizumab be considered?","authors":"İsmet Bulut, Zeynep Yegin Katran","doi":"10.15586/aei.v53i4.1349","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1349","url":null,"abstract":"<p><strong>Background: </strong>All chemotherapy agents have the potential risk of developing hypersensitivity reactions (HSRs). In patients who develop HSRs, rapid drug desensitization (RDD) enables the use of a treatment option that prevents disease progression. If RDD fails to elicit the desired results or in patients with baseline HSRs Brown grades 2-3, omalizumab may also be a treatment option. Our primary aim is to share the demographic and clinical characteristics of our patients who underwent RDD. Our secondary aim is to share our experience with omalizumab during RDD in difficult cases.</p><p><strong>Methods: </strong>This was a retrospective study of patients with immediate-HSRs to chemotherapeutic (CHT) agents. Initial HSRs were classified as grades 1, 2, or 3 based on severity. Prick/intradermal skin tests were performed with implicated agents. In grade 3 reactions and skin prick test (SPT)-positive patients, a 16-step desensitization was applied. A 12-step desensitization was applied in other patients. In 10 patients, omalizumab was administered for premedication.</p><p><strong>Results: </strong>The study analyzed data from 80 patients (F/M: 60/20). The number of patients who received different medictions was as follows: carboplatin-23, paclitaxel-22, oxaliplatin-21, dasotaxel-9, etoposide-1, docorubicin-1, pertuzimab-1, paclitaxel+herceptin-1, and bevacizumab+oxaliplatin-1. Inıtıal HSRs were grade 1: 27(%33,7) , grade 2: 30 (%37,5), and grade 3: 23(% 28,7). A total of 22 patients (27.5 %) had atopy based on SPT. Skin tests with implicated agents were done on 78 patients. For the inıtial HSR grades 1, 2, and 3, the number of positive skin test responses was 25/27, 27/29, and 17/22, respectively. A total of 377 RDDs were performed completely, but 22 patients developed 3 reactions during RDD (grade 1: 77.2%, grade 2: 13.6%, and grade 3 9%). All patients received a mean of 4.7 (minimum: 1, maximum: 23) RDDs. There was no statistical difference in the severity of reaction, system involvement, and distribution of symptoms between platinum and taxanes groups. The rate of reaction during RDD was higher in patients receiving platinum compared with taxan. Ten patients received omalizumab before RDD. Initial HSRs were grade 3 in 8 patients; the responsible agent was platinum in 5 patients; and 1 patient developed grade 3 HSR during RDD. In four patients, ınıtıal HSRs were grades 2 and 3, and desensitization was not continued when HSR developed during RDD. A total of 373 successful RDDs were performed.</p><p><strong>Conclusions: </strong>RDD is a very important treatment applied to patients with immediate-HSRs to CHT agents. Omalizumab facilitated the continuation of chemotherapy in patients with index reaction grades 2-3. It provided an opportunity for 8 of 10 patients with Grade 2-3 severe reactions to continue treatment. In our population, 98.9% (373/377) successful completion of RDDs in all chemotherapy groups demonstrates the safety of thi","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"21-30"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluating the timing of specific immunoglobulin E measurement after anaphylaxis.","authors":"Young-Il Koh, Da Woon Sim","doi":"10.15586/aei.v53i4.1329","DOIUrl":"10.15586/aei.v53i4.1329","url":null,"abstract":"<p><p>The anergic period is defined as a period of around 3-6 weeks following a systemic allergic reaction when skin test results are negative. Therefore, most guidelines recommend that physicians should conduct skin test 6 weeks after an immediate hypersensitivity reaction. However, in vitro tests, including serum-specific immunoglobulin E (IgE) measurement, are generally deemed unaffected by the anergic period. Here, we present a case of a patient with initial cefaclor-specific IgE negativity, but when tested immediately after confirmed anaphylaxis to cefaclor, the results converted to positive after the resolution of the anergic period, 8 weeks post reaction. In patients with a strong clinical suspicion of drug-induced anaphylaxis, repeating in vitro tests after the anergic period may be warranted, even if the initial results are negative. Further investigation is needed to assess whether ImmunoCAP values, similar to skin test reactivity, exhibit significant short-term variability.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"146-148"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomic profile in preschool children with transient wheezing and early onset asthma.","authors":"Ana Caroline C Dela Bianca Melo, Décio Medeiros Peixoto, Ricardo Oliveira Silva, Tatiane Priscila S Rodrigues da Luz, Amanda de Oliveira V Bastos, Emanuel Sávio Cavalcanti Sarinho, Dirceu Solé, Gustavo Falbo Wandalsen","doi":"10.15586/aei.v53i4.1327","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1327","url":null,"abstract":"<p><strong>Introduction: </strong>Early diagnosis of childhood asthma is a challenge; so we questioned whether metabolomic analysis could differentiate persistent recurrent wheezing from transient wheezing in preschoolers.</p><p><strong>Methods: </strong>Case-control study with individuals aged 4-6 years and 11 months with three or more episodes of wheezing due to bronchospasm was carried out in an allergy outpatient clinic and metabolomics laboratory from July 2021 to February 2023. Two groups were formed: persistent wheezers with multiple trigger attacks after the fourth year of life; and transient wheezers without wheezing for at least 12 months after the third year of life. Those with other wheezing disorders were excluded.</p><p><strong>Results: </strong>This study was carried out on 29 children with a mean age of 4.9 (±0.6) years-19 (65%) persistent wheezers and 10 (35%) transient wheezers. Sensitization to aeroallergens and the positive asthma predictive index were significantly higher among persistent wheezers. From the plasma hydrogen-1 NMR (¹H NMR) spectra, five best subsets were selected to discriminate between the two groups with an accuracy rate of 93.1%. Among the metabolites, valine and citrate showed higher signals and lipids and lipoproteins were higher in persistent wheezers.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"153-156"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DEPTOR alleviates LPS-induced inflammation and ER stress in WI-38 cells.","authors":"Xiangxiang Shi, Jin Ding, Bihe Zeng","doi":"10.15586/aei.v53i4.1380","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1380","url":null,"abstract":"<p><strong>Background: </strong>Pediatric pneumonia is a severe inflammatory condition frequently precipitated by bacterial endotoxins, such as lipopolysaccharide (LPS), which can elicit oxidative stress, endoplasmic reticulum (ER) stress, and apoptotic cell death. DEP domain-containing mTOR-interacting protein (DEPTOR), an endogenous inhibitor of mTOR signaling, has been implicated in the regulation of inflammation and ER homeostasis. However, its specific function in the pathogenesis of pneumonia remains poorly defined.</p><p><strong>Methods: </strong>WI-38 human fetal lung fibroblast cells were employed to establish an <i>in vitro</i> model of LPS-induced inflammation. DEPTOR was overexpressed via plasmid transfection to examine its functional role. The impact of DEPTOR on pro-inflammatory cytokine release, oxidative and ER stress responses, apoptosis, and nuclear factor <i>kappa B</i> signaling was comprehensively evaluated using quantitative real-time polymerase chain reaction, Western blot analysis, enzyme-linked-immunosorbent serologic assay, flow cytometry, and biochemical assays.</p><p><strong>Results: </strong>DEPTOR expression is significantly downregulated in LPS-stimulated WI-38 cells (P < 0.01). DEPTOR overexpression markedly suppresses LPS-induced pro-inflammatory cytokine production (P < 0.01), ameliorates oxidative and ER stress-as indicated by decreased lipid peroxidation and restoration of superoxide dismutase and <i>glutathione</i> levels (P < 0.01)-and inhibits apoptosis, reducing apoptotic cell percentages by over 10% (P < 0.01).</p><p><strong>Conclusion: </strong>These results suggest that DEPTOR confers a protective role against LPS-induced cellular injury, supporting its potential as a promising therapeutic target for mitigating.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"60-67"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The significance of SIRI and SII scores in predicting the effect of omalizumab treatment in patients with severe allergic asthma.","authors":"Sinem Berik Safçi, Özlem Erçen Diken, Sibel Kara, Tuğsan Serintürk","doi":"10.15586/aei.v53i4.1325","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1325","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the role of systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) biomarkers in predicting the response to omalizumab (OMA) treatment in patients with severe allergic asthma.</p><p><strong>Methods: </strong>A retrospective analysis was conducted to examine the correlation between the fourth-month treatment responses of patients undergoing OMA therapy for severe allergic asthma and their baseline neutrophil, lymphocyte, monocyte, and platelet values, as well as SIRI and SII scores.</p><p><strong>Results: </strong>Posttreatment asthma control scores had a positive correlation with baseline SIRI (p = 0.03, r = 0.358), SII (p = 0.04, r = 0.345), and serum neutrophil values (p = 0.01, r = 0.308), and a negative correlation with lymphocyte values (p = 0.00, r = -0.398). Baseline SII showed a negative correlation with posttreatment systemic steroid usage (mg) (p = 0.04, r = -0.247) and the number of exacerbations (p = 0.02, r = -0.269).</p><p><strong>Conclusion: </strong>SIRI and SII scores hold promise for predicting the success of OMA therapy; however, their utility needs to be validated in larger patient cohorts and further studies.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"1-6"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of type IV hypersensitivity: Prilocaine allergy.","authors":"Özge Argın, Mustafa Asım Demirkol, Yunus Bozkurt, Nihal Yıldırım, Zeynep Yegin Katran, İsmet Bulut","doi":"10.15586/aei.v53i4.1382","DOIUrl":"10.15586/aei.v53i4.1382","url":null,"abstract":"<p><p>Allergic reactions caused by local anesthetics are quite rare and these reactions often manifest as Type I (immediate-type) hypersensitivity; however, Type IV (delayed-type) hypersensitivity reactions also hold clinical significance. Type IV reactions are generally T-lymphocyte mediated and symptoms appear hours or days after antigen exposure. In this case report, a rare Type IV hypersensitivity reaction to prilocaine, an amide-type local anesthetic, is described. The patient presented to our center due to the delayed-onset skin lesions that developed after previous surgical procedures and was evaluated through comprehensive allergy testing. A positive delayed-type reaction to prilocaine was observed in the intradermal and patch tests; however, no reaction was detected in the provocation test performed with mepivacaine. This highlights the importance of careful selection of local anesthetics and consideration of Type IV hypersensitivity. Sharing such cases contributes to increased clinical awareness.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"134-137"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mechanism underlying the association between ABO blood groups and allergic diseases: an evidence-based systematic review.","authors":"Abdulrahman Salem Bahashwan","doi":"10.15586/aei.v53i4.1287","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1287","url":null,"abstract":"<p><p>This systematic review investigates the connections between ABO blood groups and allergic diseases by analyzing the existing literature to uncover underlying immunological mechanisms. Our search of PubMed, Google Scholar, and the Cochrane Database identified 35 relevant studies, with 10 articles meeting our inclusion criteria. Results suggest that blood group antigens significantly influence immune responses through interactions with immunoglobulin E (IgE) and variations in cytokine profiles. This review highlights the impact of blood group antigens on IgE and cytokine profiles, the relationship between blood group types and allergic disease susceptibility, and the role of gut microbiota in allergy development. The evidence indicates that immunological mechanisms involving IgE antibodies and cytokine signaling play a crucial role in mediating the relationship between blood groups and allergies. Our findings underscore the importance of further research into the immunological pathways linking blood groups to allergic diseases, potentially informing the development of personalized treatments and preventative measures.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"78-84"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world study in Brazilian patients with atopic dermatitis treated with dupilumab who previously received methotrexate and cyclosporine.","authors":"Cinthia Dinis da Costa, Sergio Duarte Dortas, Omar Lupi","doi":"10.15586/aei.v53i4.1311","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1311","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts patients´ quality of life. Dupilumab was Brazil´s first biologic approved to treat moderate-to-severe AD. We aimed to assess the effectiveness and safety of dupilumab in a real-life setting for 16 weeks.</p><p><strong>Methods: </strong>Fourteen patients were evaluated at weeks 0, 4, and 16 after the first dupilumab shot. At each visit, disease activity and severity, itching intensity, and impact on quality of life were measured using the EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numeric Rating Scale for itching), and DLQI (Dermatology Life Quality Index).</p><p><strong>Results: </strong>Clinical improvement observed was significant, with variation in all scores used in the study sample during the first 16 weeks of treatment (p < 0.0001).</p><p><strong>Conclusion: </strong>Dupilumab was effective and safe in our patients with moderate-to-severe AD.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"149-152"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ZBTB16 exerts anti-angiogenic effects in rheumatoid arthritis by regulating HIF-1α pathway.","authors":"Xueqin Chen, Yongmei Liu, Jiangli Xia, Xixi Ma, Linwei Hu","doi":"10.15586/aei.v53i4.1270","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1270","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is one complex chronic autoimmune disease, resulting body pain and badly affect the health of RA patients. Zinc finger and BTB domain containing 16 (ZBTB16) has been reported to participate into many diseases including osteoarthritis and osteoporosis.</p><p><strong>Objective: </strong>To verify the regulatory functions of ZBTB16 in RA progression keep dimness.</p><p><strong>Methods: </strong>The mRNA expressions were tested through RT-qPCR. The protein expressions were evaluated through western blot. The pathological changes of synovial tissues were determined through HE staining. The erosion and destruction of bone tissues were examined through safranin-O/fast green staining. The levels of TNF-α, IL-1β, IL-6 and MMP-3 were testified through ELISA. The fluorescence intensity of proteins was assessed through IF assay.</p><p><strong>Results: </strong>Firstly, it was uncovered that ZBTB16 expression was markedly reduced in the synovium tissues of RA patients through analyzing GSE55235 expression profile by GEO2R online tool. Next, ZBTB16 expression was down-regulated in synovial tissues of RA patients. Moreover, ZBTB16 can alleviate the degree of paw swelling in CIA mice. ZBTB16 improved the pathological changes of synovial tissues in CIA mice. The levels of inflammatory factors and matrix metalloproteinase were increased in CIA mice, but these impacts were reversed after ZBTB16 amplification. ZBTB16 can relieve pannus in CIA mice. Besides, the triggered GRK2/HIF-1α pathway in CIA mice can be retarded after ZBTB16 overexpression.</p><p><strong>Conclusion: </strong>ZBTB16 exerted anti-angiogenic effects in RA by blocking GRK2/HIF-1α pathway. This work hinted that ZBTB16 may be one useful target for RA treatment.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"85-92"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IFN-γ cocultured mesenchymal stem cells promote substantial immunomodulatory effects in mice models of allergic asthma.","authors":"Tao Chen, Jiaojiao Hu, Yanping Shi, Xia Li, Yujun Wang, Seyyed Shamsadin Athari, Entezar Mehrabi Nasab, Jingning Guo","doi":"10.15586/aei.v53i4.1348","DOIUrl":"https://doi.org/10.15586/aei.v53i4.1348","url":null,"abstract":"<p><p>Asthma is a debilitating lung disease characterized by airway inflammation and airflow obstruction. Immune cells, particularly T helper 2 (Th2) lymphocytes, are central players in the pathogenesis of asthma and mesenchymal stem cells (MSCs) have shown the capability of softening pathological inflammatory responses in asthma. Hence, we researched the immunopathologic effects MSCs cocultured with interferon (IFN)-γ, the main Th1 cytokine, in asthmatic mice. After isolation, MSCs were cocultured with IFN-γ and administered to asthmatic mice. Subsequent analyses included enumeration of broncho-alveolar lavage (BAL) fluid's inflammatory cells, determination of the levels of immunoglobulin E (IgE), leukotrienes (LTs), cytokines, chemokines, and histopathology assessment. The administration of IFN-γ-cocultured MSCs reduced the percentage of eosinophils in the BAL fluid and levels of IgE, LTs, cytokines, and chemokines. Also, there was a decrease in the eosinophilic infiltration of perivascular areas and periairways. IFN-γ cocultured MSCs could modulate immune responses and harness pathological events in allergic asthma.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"31-38"},"PeriodicalIF":2.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}